Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 28, 2016; 22(12): 3315-3324
Published online Mar 28, 2016. doi: 10.3748/wjg.v22.i12.3315
Published online Mar 28, 2016. doi: 10.3748/wjg.v22.i12.3315
Lipids in liver transplant recipients
Anna Hüsing, Iyad Kabar, Hartmut H Schmidt, Department of Transplant Medicine, University Hospital Münster, 48149 Münster, Germany
Author contributions: Hüsing A, Kabar I and Schmidt HH analyzed the literature and wrote the paper.
Conflict-of-interest statement: The authors declare no conflict of interest in publication of the article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Hartmut H Schmidt, MD, Professor of Medicine, Department of Transplant Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, Gebäude A14, 48149 Münster, Germany. hepar@ukmuenster.de
Telephone: +49-251-8357770 Fax: +49-251-8357771
Received: November 30, 2015
Peer-review started: December 1, 2015
First decision: December 21, 2015
Revised: January 19, 2016
Accepted: January 30, 2016
Article in press: January 30, 2016
Published online: March 28, 2016
Peer-review started: December 1, 2015
First decision: December 21, 2015
Revised: January 19, 2016
Accepted: January 30, 2016
Article in press: January 30, 2016
Published online: March 28, 2016
Core Tip
Core tip: Lipid disorders after liver transplantation are common and can significantly increase the risk of cardiovascular events in liver transplant recipients. Furthermore, dyslipidemia may also impair graft function and survival. Therefore management of dyslipidemia is of great importance in preventing cardiovascular diseases and graft dysfunction in these patients. Knowledge of the different manifestations of lipid disorders after liver transplantation, the role of immunosuppressive agents and of drug-drug interactions is therefore essential for management and follow-up of these patients.